Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Metrics to compare | RANI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRANIPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.9x | −3.1x | −0.5x | |
PEG Ratio | −0.04 | 0.01 | 0.00 | |
Price/Book | −4.6x | 0.8x | 2.6x | |
Price / LTM Sales | 21.2x | 1.6x | 3.3x | |
Upside (Analyst Target) | - | 199.5% | 40.3% | |
Fair Value Upside | Unlock | 0.0% | 4.7% | Unlock |